Adjuvant anthracycline-based versus metronomic chemotherapy versus no medical treatment for dogs with metastatic splenic hemangiosarcoma: a multi-institutional retrospective study of the Italian Society of Veterinary Oncology.
暂无分享,去创建一个
L. Marconato | S. Sabattini | G. Polton | R. Finotello | C. Agnoli | M. Vasconi | D. Stefanello | O. Capitani | M. Annoni | M. Amati | C. Chalfon | P. Mesto
[1] C. London,et al. The addition of metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma , 2018, The Journal of small animal practice.
[2] L. Marconato,et al. The use of low‐dose metronomic chemotherapy in dogs—insight into a modern cancer field , 2018, Veterinary and comparative oncology.
[3] J. Munday,et al. Does thalidomide prolong survival in dogs with splenic haemangiosarcoma? , 2018, The Journal of small animal practice.
[4] A. Mutsaers,et al. Adjuvant Doxorubicin with or without Metronomic Cyclophosphamide for Canine Splenic Hemangiosarcoma. , 2017, Journal of the American Animal Hospital Association.
[5] L. Marconato,et al. A retrospective analysis of chemotherapy switch suggests improved outcome in surgically removed, biologically aggressive canine haemangiosarcoma† , 2017, Veterinary and comparative oncology.
[6] L. Marconato,et al. Comparison of doxorubicin–cyclophosphamide with doxorubicin–dacarbazine for the adjuvant treatment of canine hemangiosarcoma , 2017, Veterinary and comparative oncology.
[7] D. Thamm,et al. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. , 2015, Veterinary and comparative oncology.
[8] L. Price,et al. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012). , 2015, Journal of the American Veterinary Medical Association.
[9] W. Kisseberth,et al. VAC protocol for treatment of dogs with stage III hemangiosarcoma. , 2013, Journal of the American Animal Hospital Association.
[10] D. Knapp,et al. Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma. , 2013, Journal of the American Veterinary Medical Association.
[11] D. Knapp,et al. Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer. , 2012, Veterinary and comparative oncology.
[12] J. Bryan,et al. Tolerability of metronomic administration of lomustine in dogs with cancer. , 2011, Journal of veterinary internal medicine.
[13] S. Dow,et al. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. , 2008, Journal of veterinary internal medicine.
[14] Tara N. Hammond,et al. Prevalence of hemangiosarcoma in anemic dogs with a splenic mass and hemoperitoneum requiring a transfusion: 71 cases (2003-2005). , 2008, Journal of the American Veterinary Medical Association.
[15] G. Monteith,et al. Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004). , 2007, Journal of the American Veterinary Medical Association.
[16] R. Poppenga,et al. Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma. , 2007, Journal of veterinary internal medicine.
[17] S. Dow,et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. , 2007, Journal of veterinary internal medicine.
[18] J. Modiano,et al. Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. , 2006, Experimental hematology.
[19] P. Schultheiss. A Retrospective Study of Visceral and Nonvisceral Hemangiosarcoma and Hemangiomas in Domestic Animals , 2004, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.
[20] Robert S. Kerbel,et al. The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.
[21] F. Shofer,et al. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma. , 2004, Journal of veterinary internal medicine.
[22] E. Hardie,et al. Acute nontraumatic hemoabdomen in the dog: a retrospective analysis of 39 cases (1987-2001). , 2003, Journal of the American Animal Hospital Association.
[23] R. Kerbel,et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. , 2003, Cancer research.
[24] M. Piccart-Gebhart. Mathematics and oncology: a match for life? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] C. Couto,et al. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. , 1991, Journal of veterinary internal medicine.
[26] D. W. Hayden,et al. Intracranial lesions in dogs with hemangiosarcoma. , 1989, Journal of veterinary internal medicine.
[27] B. Powers,et al. Splenomegaly in Dogs , 1989 .
[28] M. Quinn,et al. Low dose cyclophosphamide: Mechanisms of T cell modulation. , 2016, Cancer treatment reviews.
[29] Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. , 2004, Veterinary and comparative oncology.
[30] E. Macewen,et al. Canine hemangiosarcoma: retrospective analysis of 104 cases. , 1985, Journal of the American Veterinary Medical Association.